In the article by Nishimura M et al., entitled ‘Possible inhibitory effect of erythropoiesis-stimulating agents at the predialysis stage on early-phase coronary events after hemodialysis initiation’ [Cardiorenal Med 2017;7:21–30, DOI:10.1159/000448009], an error in the serum ferritin concentrations included in table 3 was identified after online publication of this paper in CardioRenal Medicine. This is a simple technical error and does not affect the point of any argument of this paper.
Table 3.
Differences in clinical data at hemodialysis initiation among the subgroups divided by blood Hb concentration and the use of ESAs
| Hb ≥8.5 g/dl, ESA+ (n = 82) | Hb <8.5 g/dl, ESA+ (n = 36) | Hb ≥8.5 g/dl, ESA− (n = 38) | Hb <8.5 g/dl, ESA− (n = 86) | |
|---|---|---|---|---|
| Males, n (%) | 52 (63.4) | 23 (63.9) | 28 (73.7) | 52 (60.5) |
| Age, years | 64.2 ± 14.4 | 64.5 ± 12.2 | 63.7 ± 15.0 | 67.8 ± 10.6 |
| Body mass index | 18.8 ± 3.8 | 19.1 ± 3.6 | 19.5 ± 4.3 | 19.2 ± 4.4 |
| Diabetes mellitus, n (%) | 47 (57.3) | 17 (47.2) | 21 (55.3) | 48 (55.8) |
| Systolic blood pressure, mm Hg | 155.6 ± 26.2 | 149.4 ± 23.4 | 158.7 ± 26.8 | 154.9 ± 25.2 |
| Diastolic blood pressure, mm Hg | 82.4 ± 15.7b | 76.9 ± 12.9 | 83.7 ± 12.8 | 76.2 ± 14.1 |
| Cardiothoracic ratio, % | 52.4 ± 6.4 | 50.9 ± 4.7 | 51.3 ± 6.2 | 53.4 ± 5.7 |
| Left ventricular ejection fraction, % | 62.2 ± 13.6 | 60.7 ± 13.6 | 61.0 ± 12.5 | 62.2 ± 10.9 |
| Left ventricular mass index | 139.5 ± 49.7 | 140.3 ± 58.3 | 158.9 ± 51.5 | 153.2 ± 84.6 |
| Blood Hb, g/dl | 9.8 ± 0.9a,c,d | 7.5 ± 0.7 | 9.2 ± 0.7a,c | 7.3 ± 0.8 |
| Serum creatinine, mg/dl | 8.4 ± 2.7 | 9.6 ± 3.7 | 8.4 ± 3.4 | 8.8 ± 3.3 |
| Serum albumin, g/dl | 3.5 ± 0.5b | 3.4 ± 0.5 | 3.4 ± 0.5 | 3.3 ± 0.5 |
| Serum ferritin, ng/ml | 155.1 ± 139.3 | 165.5 ± 132.3 | 168.2 ± 220.1 | 229.1 ± 344.1 |
| Serum C-reactive protein, mg/dl Medications, n (%) | 0.245 ± 0.157 | 0.299 ± 0.156 | 0.242 ± 0.187 | 0.239 ± 0.163 |
| Oral iron | 52 (63.4) | 25 (69.4) | 25 (65.8) | 47 (54.7) |
| Calcium channel blockers | 67 (81.7) | 30 (83.3) | 24 (63.2) | 57 (66.3) |
| RAS inhibitors | 65 (79.3)b | 14 (38.9) | 24 (63.2) | 35 (40.7) |
| Alpha-1 blockers | 18 (22.0) | 6 (16.7) | 7 (18.4) | 15 (17.4) |
| Beta blockers | 20 (24.4) | 7 (19.4) | 8 (21.1) | 15 (17.4) |
| Antiplatelet drugs | 20 (24.4) | 7 (19.4) | 10 (26.3) | 16 (18.6) |
| Statins | 19 (23.2) | 6 (16.7) | 11 (29.0) | 12 (14.0) |
p < 0.001 versus Hb <8.5 g/dl, ESA-;
p < 0.05 versus Hb <8.5 g/dl, ESA-;
p < 0.001 versus Hb <8.5 g/dl, ESA+;
p < 0.05 versus Hb ≥8.5 g/dl, ESA-.
The corrected values of serum ferritin concentrations in table 3 are as follows: Hb ≥8.5 g/dl, ESA+: 155.1 ± 139.3 ng/ml; Hb <8.5 g/dl, ESA+: 165.5 ± 132.3 ng/ml; Hb ≥8.5 g/dl, ESA−: 168.2 ± 220.1 ng/ml; Hb <8.5 g/dl, ESA−: 229.1 ± 344.1 ng/ml.